Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure.

@article{Kherani2004MacrophageIS,
  title={Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure.},
  author={Aftab R Kherani and Garrett W Moss and Hua Zhou and Anguo Gu and Geping Zhang and Allison R Schulman and Jennifer M Fal and Robert A. Sorabella and Terry F Plasse and Liu Rui and Shunichi Homma and Daniel Burkhoff and Mehmet C Oz and Jie Wang},
  journal={Journal of cardiovascular pharmacology},
  year={2004},
  volume={44 6},
  pages={665-71}
}
Pharmaceutical agents aimed at reducing tumor necrosis factor-alpha (TNF-alpha) levels appeared to be attractive possibilities in the medical management of heart failure, as heart failure was shown to be associated with high TNF-alpha levels. However, therapies specifically targeting TNF-alpha failed to show any survival benefit. We examined whether a broad inhibition of inflammatory cytokine production secondary to macrophage inhibition would be more effective at improving cardiac function in… CONTINUE READING